Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 389

1.

Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres.

Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J.

Aliment Pharmacol Ther. 2019 Oct 15. doi: 10.1111/apt.15529. [Epub ahead of print]

PMID:
31617224
2.

Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.

Corbaux P, Maillet D, Boespflug A, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Dalle S, Falandry C, Péron J.

Eur J Cancer. 2019 Oct 4;121:192-201. doi: 10.1016/j.ejca.2019.08.027. [Epub ahead of print]

PMID:
31590080
3.

A prospective study identifying predictive factors of cardiac decompensation after TIPS: the Toulouse algorithm.

Billey C, Billet S, Robic MA, Cognet T, Guillaume M, Vinel JP, Péron JM, Lairez O, Bureau C.

Hepatology. 2019 Sep 12. doi: 10.1002/hep.30934. [Epub ahead of print]

PMID:
31512743
4.

Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies.

Corbaux P, El-Madani M, Tod M, Péron J, Maillet D, Lopez J, Freyer G, You B.

Eur J Cancer. 2019 Oct;120:40-46. doi: 10.1016/j.ejca.2019.08.002. Epub 2019 Aug 31. Review.

PMID:
31479946
5.

NLRP3 gain-of-function in CD4+ T lymphocytes ameliorates experimental autoimmune encephalomyelitis.

Braga TT, Brandao WN, Azevedo H, Terra FF, Melo ACL, Pereira FV, Andrade-Oliveira V, Hiyane MI, Peron JPS, Camara NOS.

Clin Sci (Lond). 2019 Sep 13;133(17):1901-1916. doi: 10.1042/CS20190506. Print 2019 Sep 13.

PMID:
31471462
6.

Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules.

Mokrane FZ, Lu L, Vavasseur A, Otal P, Peron JM, Luk L, Yang H, Ammari S, Saenger Y, Rousseau H, Zhao B, Schwartz LH, Dercle L.

Eur Radiol. 2019 Aug 23. doi: 10.1007/s00330-019-06347-w. [Epub ahead of print]

PMID:
31444598
7.

Breast cancer specialists' perspective on their role in their patients' return to work: A qualitative study.

Lamort-Bouché M, Péron J, Broc G, Kochan A, Jordan C, Letrilliart L, Fervers B, Fassier JB; FASTRACS Group.

Scand J Work Environ Health. 2019 Aug 21. pii: 3847. doi: 10.5271/sjweh.3847. [Epub ahead of print]

8.

Therapeutic treatment with Modafinil decreases the severity of experimental autoimmune encephalomyelitis in mice.

Brandão WN, Andersen ML, Palermo-Neto J, Peron JP, Zager A.

Int Immunopharmacol. 2019 Oct;75:105809. doi: 10.1016/j.intimp.2019.105809. Epub 2019 Aug 16.

PMID:
31425975
9.

Cerebellar contribution to vocal emotion decoding: Insights from stroke and neuroimaging.

Thomasson M, Saj A, Benis D, Grandjean D, Assal F, Péron J.

Neuropsychologia. 2019 Sep;132:107141. doi: 10.1016/j.neuropsychologia.2019.107141. Epub 2019 Jul 12.

PMID:
31306617
10.

Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.

Wang H, Lekbaby B, Fares N, Augustin J, Attout T, Schnuriger A, Cassard AM, Panasyuk G, Perlemuter G, Bieche I, Vacher S, Selves J, Péron JM, Bancel B, Merle P, Kremsdorf D, Hall J, Chemin I, Soussan P.

Hepatol Int. 2019 Jul;13(4):454-467. doi: 10.1007/s12072-019-09950-7. Epub 2019 May 28.

PMID:
31140152
11.

New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.

Boursier J, Guillaume M, Leroy V, Irlès M, Roux M, Lannes A, Foucher J, Zuberbuhler F, Delabaudière C, Barthelon J, Michalak S, Hiriart JB, Peron JM, Gerster T, Le Bail B, Riou J, Hunault G, Merrouche W, Oberti F, Pelade L, Fouchard I, Bureau C, Calès P, de Ledinghen V.

J Hepatol. 2019 Aug;71(2):389-396. doi: 10.1016/j.jhep.2019.04.020. Epub 2019 May 16.

PMID:
31102719
12.

Shame in Parkinson'S Disease: A Review.

Angulo J, Fleury V, Péron JA, Penzenstadler L, Zullino D, Krack P.

J Parkinsons Dis. 2019;9(3):489-499. doi: 10.3233/JPD-181462.

13.

Is Nutritional Screening of Patients with Lung Cancer Optimal? An Expert Opinion Survey of French Physicians and Surgeons.

Corbaux P, Fontaine-Delaruelle C, Souquet PJ, Couraud S, Morel H, Tronc F, Eker E, Peron J, Raynard B.

Nutr Cancer. 2019;71(6):971-980. doi: 10.1080/01635581.2019.1595051. Epub 2019 May 9.

PMID:
31070050
14.

Viral receptors for flaviviruses: Not only gatekeepers.

Oliveira LG, Peron JPS.

J Leukoc Biol. 2019 Sep;106(3):695-701. doi: 10.1002/JLB.MR1118-460R. Epub 2019 May 7. Review.

PMID:
31063609
15.

Subthalamic nucleus local field potentials recordings reveal subtle effects of promised reward during conflict resolution in Parkinson's disease.

Duprez J, Houvenaghel JF, Dondaine T, Péron J, Haegelen C, Drapier S, Modolo J, Jannin P, Vérin M, Sauleau P.

Neuroimage. 2019 Aug 15;197:232-242. doi: 10.1016/j.neuroimage.2019.04.071. Epub 2019 Apr 30.

16.

High dose of dexamethasone protects against EAE-induced motor deficits but impairs learning/memory in C57BL/6 mice.

Dos Santos N, Novaes LS, Dragunas G, Rodrigues JR, Brandão W, Camarini R, Peron JPS, Munhoz CD.

Sci Rep. 2019 Apr 30;9(1):6673. doi: 10.1038/s41598-019-43217-3.

17.

Re: Everything is awesome: Don't forget the lego.

de Rojas T, Neven A, Kelly S, Péron J.

J Paediatr Child Health. 2019 Apr;55(4):485-486. doi: 10.1111/jpc.14403. No abstract available.

PMID:
30957334
18.

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.

Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V.

Br J Cancer. 2019 Apr;120(9):896-902. doi: 10.1038/s41416-019-0443-4. Epub 2019 Apr 4.

PMID:
30944458
19.

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.

Colomban O, Tod M, Leary A, Ray-Coquard I, Lortholary A, Hardy-Bessard AC, Pfisterer J, Du Bois A, Kurzeder C, Burges A, Péron J, Freyer G, You B.

Clin Cancer Res. 2019 Sep 1;25(17):5342-5350. doi: 10.1158/1078-0432.CCR-18-3335. Epub 2019 Apr 1.

PMID:
30936122
20.

1H NMR quantification of spray dried and spray freeze-dried saccharide carriers in dry powder inhaler formulations.

Babenko M, Peron JR, Kaialy W, Calabrese G, Alany RG, ElShaer A.

Int J Pharm. 2019 Jun 10;564:318-328. doi: 10.1016/j.ijpharm.2019.03.030. Epub 2019 Mar 16.

PMID:
30890450
21.

Assessing long-term survival benefits of immune checkpoint inhibitors using the net survival benefit.

Péron J, Lambert A, Munier S, Ozenne B, Giai J, Roy P, Dalle S, Machingura A, Maucort-Boulch D, Buyse M.

J Natl Cancer Inst. 2019 Mar 5. pii: djz030. doi: 10.1093/jnci/djz030. [Epub ahead of print]

PMID:
30838402
22.

O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).

Lemelin A, Barritault M, Hervieu V, Payen L, Péron J, Couvelard A, Cros J, Scoazec JY, Bin S, Villeneuve L, Lombard-Bohas C, Walter T; MGMT-NET investigators.

Dig Liver Dis. 2019 Apr;51(4):595-599. doi: 10.1016/j.dld.2019.02.001. Epub 2019 Feb 14.

PMID:
30824408
23.

Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study.

Pischke S, Peron JM, von Wulffen M, von Felden J, Höner Zu Siederdissen C, Fournier S, Lütgehetmann M, Iking-Konert C, Bettinger D, Par G, Thimme R, Cantagrel A, Lohse AW, Wedemeyer H, de Man R, Mallet V.

Viruses. 2019 Feb 22;11(2). pii: E186. doi: 10.3390/v11020186.

24.

29OThe 18-year-old clinical trial inclusion limit is a major barrier in the access to immunotherapies and targeted therapies for adolescents and young adults (AYAs) with cancer.

de Rojas T, Neven A, Garcia-Abos M, Moreno L, Gaspar N, Peron J.

Ann Oncol. 2019 Feb 1;30(Supplement_1). pii: mdz026. doi: 10.1093/annonc/mdz026. No abstract available.

PMID:
30810198
25.

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.

Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group.

Gastroenterology. 2019 Mar;156(4):997-1009.e5. doi: 10.1053/j.gastro.2018.11.053. Epub 2019 Feb 13.

PMID:
30768988
26.

A semi-automatic approach to the characterisation of dark chocolate by Nuclear Magnetic Resonance and multivariate analysis.

Le Gresley A, Peron JR.

Food Chem. 2019 Mar 1;275:385-389. doi: 10.1016/j.foodchem.2018.09.089. Epub 2018 Sep 14.

PMID:
30724211
27.

Changes in the Use of Comprehensive Geriatric Assessment in Clinical Trials for Older Patients with Cancer over Time.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J.

Oncologist. 2019 Aug;24(8):1089-1094. doi: 10.1634/theoncologist.2018-0493. Epub 2019 Feb 1.

PMID:
30710065
28.

A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial.

Péron J, Marreaud S, Staelens D, Raveloarivahy T, Nzokirantevye A, Flament J, Steuve J, Lia M, Collette L, Schöffski P.

Eur J Cancer. 2019 Mar;109:192-195. doi: 10.1016/j.ejca.2018.12.013. Epub 2019 Jan 14. No abstract available.

PMID:
30655100
29.

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.

Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S, Péron J.

Int J Cancer. 2019 Aug 1;145(3):639-648. doi: 10.1002/ijc.32132. Epub 2019 Feb 4.

PMID:
30653255
30.

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.

Friedlaender A, Vuilleumier A, Viassolo V, Ayme A, De Talhouet S, Combes JD, Peron J, Bodmer A, Giraud S, Buisson A, Bonadona V, Gauchat-Bouchardy I, Tredan O, Chappuis PO, Labidi-Galy SI.

Breast Cancer Res Treat. 2019 Apr;174(3):775-783. doi: 10.1007/s10549-018-05127-2. Epub 2019 Jan 11.

PMID:
30635808
31.

The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma.

Péron J, Giai J, Maucort-Boulch D, Buyse M.

Pancreas. 2019 Feb;48(2):275-280. doi: 10.1097/MPA.0000000000001234.

PMID:
30629024
32.

[Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: Case report of a complete pathological response and review of the literature].

Pouëdras J, Izar F, Muscari F, Parent L, Breibach F, Péron JM, Otal P, Suc B, Rives M, Modesto A.

Cancer Radiother. 2018 Dec;22(8):797-801. doi: 10.1016/j.canrad.2018.04.001. Epub 2018 Oct 26. Review. French.

PMID:
30523795
33.

Liver transplantation in patients with liver failure related to exertional heatstroke.

Ichai P, Laurent-Bellue A, Camus C, Moreau D, Boutonnet M, Saliba F, Peron JM, Ichai C, Gregoire E, Aigle L, Cousty J, Quinart A, Pons B, Boudon M, André S, Coilly A, Antonini T, Guettier C, Samuel D.

J Hepatol. 2019 Mar;70(3):431-439. doi: 10.1016/j.jhep.2018.11.024. Epub 2018 Dec 4.

PMID:
30521841
34.

Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort.

Brichler S, Nahon P, Zoulim F, Layese R, Bourcier V, Audureau E, Sutton A, Letouze E, Cagnot C, Marcellin P, Guyader D, Roulot D, Pol S, de Ledinghen V, Zarski JP, Calès P, Tran A, Peron JM, Mallat A, Riachi G, Grange JD, Blanc JF, Bacq Y, Ouzan D, Bronowicki JP, Mathurin P, Larrey D, Alric L, Attali P, Serfaty L, Pilette C, Bourlière M, Thabut D, Silvain C, Wartelle C, Zucman D, Christidis C, Roudot-Thoraval F, Ganne-Carrie N; ANRS CO12 CirVir study group.

J Viral Hepat. 2019 Mar;26(3):384-396. doi: 10.1111/jvh.13029. Epub 2019 Jan 16.

PMID:
30380181
35.

Performance of a commercial assay for detecting and quantifying HEV RNA in faeces.

Abravanel F, Lacipière A, Lhomme S, Dubois M, Minier L, Peron JM, Alric L, Kamar N, Izopet J.

J Clin Virol. 2018 Dec;109:1-5. doi: 10.1016/j.jcv.2018.10.003. Epub 2018 Oct 10.

PMID:
30336371
36.

The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis.

Péron J, Mercier F, Tuech JJ, Younan R, Sideris L, Gelli M, Dumont F, Le Roy B, Sgarbura O, Lo Dico R, Bibeau F, Glehen O, Passot G; on behalf BIG-RENAPE working groups.

Surgery. 2019 Feb;165(2):476-484. doi: 10.1016/j.surg.2018.07.027. Epub 2018 Sep 7.

PMID:
30197280
37.

Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.

Ganne-Carrié N, Chaffaut C, Bourcier V, Archambeaud I, Perarnau JM, Oberti F, Roulot D, Moreno C, Louvet A, Dao T, Moirand R, Goria O, Nguyen-Khac E, Carbonell N, Antonini T, Pol S, de Ledinghen V, Ozenne V, Henrion J, Péron JM, Tran A, Perlemuter G, Amiot X, Zarski JP, Beaugrand M, Chevret S; for CIRRAL Group.

J Hepatol. 2018 Dec;69(6):1274-1283. doi: 10.1016/j.jhep.2018.07.022. Epub 2018 Aug 6.

38.

Control of catalytic nanoparticle synthesis: general discussion.

Adishev A, Arrigo R, Baletto F, Bordet A, Bukhtiyarov V, Carosso M, Catlow R, Conway M, Davies J, Davies P, De Masi D, Demirci C, Edwards JK, Friend C, Gallarati S, Hargreaves J, Huang H, Hutchings G, Lai S, Lamberti C, Macino M, Marchant D, Murayama T, Odarchenko Y, Peron J, Prati L, Quinson J, Richards N, Rogers S, Russell A, Selvam P, Shah P, Shozi M, Skylaris CK, Soulantica K, Spolaore F, Tooze B, Torrente-Murciano L, Trunschke A, Venezia B, Walker J, Whiston K.

Faraday Discuss. 2018 Sep 3;208(0):471-495. doi: 10.1039/c8fd90015a. No abstract available.

PMID:
30091432
39.

Application of new nanoparticle structures as catalysts: general discussion.

Baletto F, Boeije M, Bordet A, Brinkert K, Catlow R, Davies J, Dononelli W, Freund HJ, Friend C, Gates B, Genest A, Guan S, Hardacre C, Hargreaves J, Huang H, Hutchings G, Johnston R, Lai S, Lamberti C, Marbaix J, Miranda CR, Nome R, Peron J, Quinson J, Richards N, Roesch N, Russell A, Said S, Selvam P, Sermon P, Shozi M, Skylaris CK, Spolaore F, Walker J, Whiston K, Willock D.

Faraday Discuss. 2018 Sep 3;208(0):575-593. doi: 10.1039/c8fd90016g. No abstract available.

PMID:
30090887
40.

Hemispheric specialization of the basal ganglia during vocal emotion decoding: Evidence from asymmetric Parkinson's disease and 18FDG PET.

Stirnimann N, N'Diaye K, Jeune FL, Houvenaghel JF, Robert G, Drapier S, Drapier D, Grandjean D, Vérin M, Péron J.

Neuropsychologia. 2018 Oct;119:1-11. doi: 10.1016/j.neuropsychologia.2018.07.023. Epub 2018 Jul 21.

PMID:
30040955
41.

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19.

PMID:
30031138
42.

Functional atlases for analysis of motor and neuropsychological outcomes after medial globus pallidus and subthalamic stimulation.

Haegelen C, Baumgarten C, Houvenaghel JF, Zhao Y, Péron J, Drapier S, Jannin P, Morandi X.

PLoS One. 2018 Jul 13;13(7):e0200262. doi: 10.1371/journal.pone.0200262. eCollection 2018. Erratum in: PLoS One. 2019 Oct 3;14(10):e0223693.

43.

Acute hepatitis E in French patients and neurological manifestations.

Abravanel F, Pique J, Couturier E, Nicot F, Dimeglio C, Lhomme S, Chiabrando J, Saune K, Péron JM, Kamar N, Evrard S, de Valk H, Cintas P, Izopet J; HEV study group.

J Infect. 2018 Sep;77(3):220-226. doi: 10.1016/j.jinf.2018.06.007. Epub 2018 Jul 10.

PMID:
29966614
44.

Interventions Developed with the Intervention Mapping Protocol in Work Disability Prevention: A Systematic Review of the Literature.

Fassier JB, Sarnin P, Rouat S, Péron J, Kok G, Letrilliart L, Lamort-Bouché M.

J Occup Rehabil. 2019 Mar;29(1):11-24. doi: 10.1007/s10926-018-9776-8. Review.

PMID:
29948471
45.

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

Saad ED, Zalcberg JR, Péron J, Coart E, Burzykowski T, Buyse M.

J Natl Cancer Inst. 2018 Mar 1;110(3):232-240. doi: 10.1093/jnci/djx179. Review.

PMID:
29933439
46.

[Hepatic and extra-hepatic manifestations of hepatitis E virus infection].

Blasco-Perrin H, Péron JM.

Presse Med. 2018 Jul - Aug;47(7-8 Pt 1):620-624. doi: 10.1016/j.lpm.2015.04.017. Epub 2018 Jun 13. French.

PMID:
29909165
47.

The polyol process: a unique method for easy access to metal nanoparticles with tailored sizes, shapes and compositions.

Fiévet F, Ammar-Merah S, Brayner R, Chau F, Giraud M, Mammeri F, Peron J, Piquemal JY, Sicard L, Viau G.

Chem Soc Rev. 2018 Jul 17;47(14):5187-5233. doi: 10.1039/c7cs00777a. Review.

PMID:
29901663
48.

Meta-Research on Oncology Trials: A Toolkit for Researchers with Limited Resources.

Riechelmann RP, Péron J, Seruga B, Saad ED.

Oncologist. 2018 Dec;23(12):1467-1473. doi: 10.1634/theoncologist.2018-0043. Epub 2018 May 16.

PMID:
29769384
49.

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Aug;155(2):431-442.e10. doi: 10.1053/j.gastro.2018.04.027. Epub 2018 May 3.

PMID:
29729258
50.

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.

Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, DI Martino V, Sutton A, Letouzé E, Audureau E, Roudot-Thoraval F; ANRS CO12 CirVir Group.

Hepatology. 2018 Oct;68(4):1245-1259. doi: 10.1002/hep.30034. Epub 2018 Jul 10.

PMID:
29663511

Supplemental Content

Support Center